Not a ton of news as the year closes down. It seems like the market wants to whiplash investors as we bounce around with no clear trends. It does not.
BriaCell presented some data from the ongoing Phase IIa combination clinical trial of Bria-IMT™ with Merck’s (NYSE: MRK) KEYTRUDA® [(pembrolizumab)], as listed in ClinicalTrials.gov as NCT03328026, in advanced breast cancer.
The market can always surprise and I was surprised yesterday with the sector strength. The broader market did better than I expected but the sector clearly outperformed. It is only.
Yesterday was a good day but not as broad based as one would have hoped. Today will be telling in that the confusion over the China “trade deal” has only.
We are at an interesting place for the sector. The XBI is approaching the upper end of the downtrend, which has been acting as resistance. I am not totally convinced.
After a nice long holiday break, I figured there might be some more news to start the week but apparently not. The sector is off to a good start but.
This should be a relatively slow week but with ASH late breaking abstracts coming out later, it might not be completely devoid of news. There is a little more hope.
In a previous interview, BriaCell (TSX:BCT.V) (OTCQB:BCTXF) (or the Company)’s President and CEO, Dr. Bill Williams cited as a near-term catalyst data from the Company’s ongoing Phase IIa combination clinical.
Today is an important day for the sector. We are at very long term support (the 200 week MA) that has rarely been breached (occasionally but never in a sustained.
A rough start to the week. The market just feels heavy and looks like it wants to break through the recent lows. It looked for a little like it wanted.
The midterm elections are over and now we have a couple hour break before the 2020 presidential campaigning begins. The split congress is likely positive for the markets as they.